How should multidrug-resistant Escherichia coli infections be managed?

Management of Multidrug-Resistant E. coli Infections

For severe MDR E. coli infections, prioritize newer beta-lactam/beta-lactamase inhibitor combinations (ceftazidime-avibactam, meropenem-vaborbactam) or cefiderocol if active in vitro, reserving carbapenems for carbapenem-resistant strains with MIC ≤8 mg/L. 1

Severity-Based Treatment Algorithm

Severe Infections (Sepsis, Complicated UTI, Pneumonia)

For carbapenem-resistant E. coli (CRE):

• First-line: Meropenem-vaborbactam or ceftazidime-avibactam if susceptible in vitro 1
• For metallo-β-lactamase producers: Cefiderocol as monotherapy 1, or aztreonam plus ceftazidime-avibactam combination 1
• When only older agents active: Use combination therapy with ≥2 active drugs from polymyxins, aminoglycosides (including plazomicin), tigecycline, or fosfomycin 1

Avoid tigecycline for bloodstream infections and pneumonia unless no alternatives exist; if necessary for pneumonia, use high-dose regimens 1

Do not use combination therapy if treating with ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol and the organism is susceptible 1

Non-Severe Infections

For complicated UTI with CRE:

• Aminoglycosides (including plazomicin) preferred over tigecycline 1
• Fosfomycin shows 100% susceptibility in recent Australian data for ESBL-producing E. coli 2
• Mecillinam demonstrates 97% susceptibility against MDR E. coli 2

Monotherapy is acceptable when using an active older agent selected based on susceptibility testing and infection source 1

Resistance Pattern-Specific Considerations

ESBL-Producing E. coli (Non-Carbapenem-Resistant)

Recent surveillance shows concerning resistance rates: 25.9% to ciprofloxacin and 28.8% to trimethoprim-sulfamethoxazole 3. Avoid fluoroquinolones empirically given 52.7% resistance in nursing home populations 4.

Oral options for step-down therapy:

• Mecillinam (97% susceptible, MIC90 low) 2
• Tebipenem (MIC90 0.125 mg/L) 2
• Sulopenem (MIC90 0.5 mg/L) 2
• Fosfomycin (100% susceptible) 2
• Omadacycline (95% susceptible) 2

Carbapenem-Based Therapy Considerations

Avoid carbapenem-based combinations unless meropenem MIC is ≤8 mg/L, where high-dose extended-infusion meropenem may be used as part of combination therapy if newer agents unavailable 1

Combination Therapy Evidence

The evidence for combination therapy remains conflicting across 35 observational studies with variable definitions of "combination" (2-5 antibiotics with inconsistent in vitro activity) 1. Combination therapy shows benefit primarily in:

• Severe disease presentations 1
• Infections susceptible only to older agents (polymyxins, aminoglycosides, tigecycline, fosfomycin) 1
• MBL-producing strains requiring aztreonam-ceftazidime/avibactam 1

Polymyxin-based combinations (particularly colistin plus meropenem or rifampicin) demonstrate synergistic killing in vitro and preclinical models, though high-quality RCT data remain lacking 5

Critical Pitfalls

• Do not rely on fluoroquinolones empirically: Resistance exceeds 50% in many populations 3, 4
• Avoid tigecycline monotherapy for bloodstream infections: Associated with poor outcomes 1
• Do not use carbapenem combinations routinely: Only justified when MIC ≤8 mg/L and newer agents unavailable 1
• Verify in vitro susceptibility: MDR definitions vary; 13.8% of invasive E. coli are ESBL-producers with unpredictable susceptibility patterns 3

Special Populations

Older adults (≥60 years): Face 7.3-fold higher incidence (225.0 vs 30.6 per 100,000) with 7.9% mortality 3. Diabetes patients comprise 34% of cases and require aggressive source control 3.

Nursing home residents: Experience 23.5% hospitalization rate and 5.8% 30-day mortality with IED, warranting lower threshold for parenteral therapy 4